Procedures required during the follow-up period included additional laser in 20 eyes (72%), in 17 for PDR and in three for macular edema, anti-VEGF with bevacizumab for macular edema in two eyes, and PPV in 17 eyes (60%). The gene discussed is VEGFA; the disease is macular retinal edema.